Identfication of tumor-specific and tumor-associated antigens for potential clinical application in vaccination studies - Part: Squamous cell cancer of the head and neck
Recruiting
- Conditions
- C10Malignant neoplasm of larynxC32Malignant neoplasm of oropharynx
- Registration Number
- DRKS00014018
- Lead Sponsor
- niversitätsklinikum Tübingen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Squamous cell carcinoma of the head and neck with indication for surgical resection
Exclusion Criteria
- Relevant comorbidities
- no indication for surgery
- insufficient amount of tumor material
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of HLA-presented tumor-associated and/or tumor-specific ligands (HLA-ligandome)
- Secondary Outcome Measures
Name Time Method - Evaluation of the immunological relevance of the identified ligands<br>- Evaluation of metabolic pathways
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What tumor-specific antigens are being identified in DRKS00014018 for head and neck squamous cell carcinoma (HNSCC)?
How do tumor-associated antigens in HNSCC correlate with immune checkpoint inhibitor response in observational studies?
What molecular targets are prioritized for vaccination in laryngeal and oropharyngeal malignancies with high mutational burden?
Are there comparative studies on antigen-based vaccines versus standard-of-care for C10 and C32 malignant neoplasms?
What adverse event profiles are associated with antigen identification approaches in head and neck cancer immunotherapy?